Czechia· CZ-0290199
AUMSEQA
A aumolertinib product containing aumolertinib mesilate, registered in Czechia by SFL Pharmaceuticals Deutschland GmbH, Lörrach. The same ATC class is registered in 8 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Aumolertinib is registered in 8 of 19 countries.
Countries holding a registration under ATC L01EB11 (aumolertinib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 5 of them publish a price we can compare per daily dose
Aumolertinib · ATC L01EB11
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- AUMOLERTINIB MESILATE
- Manufacturer
- SFL Pharmaceuticals Deutschland GmbH, Lörrach
- Country
- Czechia (CZ)
- ATC code
- L01EB11
- ATC class
- Aumolertinib
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aumolertinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAumseqa 55 mgSfl Pharmaceuticals Deutschland
- FinlandAumseqaSFL Pharmaceuticals Deutschland GmbH
- IrelandAumseqa 55 mg film-coated tabletsSFL Pharmaceuticals Deutschland GmbH
- IcelandAumseqaSFL Pharmaceuticals Deutschland GmbH
- NetherlandsAumseqa 55 mg filmomhulde tabletSFL Pharmaceuticals Deutschland GmbH
- PolandAumseqaSFL Pharmaceuticals Deutschland GmbH
- SwedenAumseqa 55 mg Filmdragerad tablettSFL Pharmaceuticals Deutschland GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/10759fae-978a-4e3e-b81c-3a4276b8b412 GET /v1/drugs/10759fae-978a-4e3e-b81c-3a4276b8b412?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "55MG",
"pack_size": "60",
"substance": "AUMOLERTINIB MESILATE",
"cz_kod_sukl": "0290199",
"product_type": "CH",
"substance_codes": "4748",
"registration_state": "R",
"registration_number": "EU/1/25/2006/001"
}See everything about aumolertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.